Dimethyl Sulfoxide Enhances HLA Peptide Identification
<b>Background:</b> Mass spectrometry (MS)-based immunopeptidomics has emerged as the gold standard for profiling HLA-bound peptides, yet detection remains challenging due to their non-tryptic nature, variable lengths, and lack of basic residues, which limit ionisation and fragmentation efficiency. <b>Methods:</b> To address these limitations, we investigated the impact of incorporating 5% dimethyl sulfoxide (DMSO) into LC-MS/MS mobile-phase buffers on immunopeptidomic workflows. Using B-lymphoblastoid cell lines expressing HLA class I and II alleles and elastase-digested HeLa lysates as a surrogate for non-tryptic peptides, we assessed peptide identification, ionisation efficiency, charge state distribution, and fragmentation quality. <b>Results:</b> DMSO significantly increased peptide identifications across all sample types, with gains of ~1.33 folds for HLA class I, ~1.55 folds for HLA class II, and ~1.24 folds for elastase digests. Improvements were systematic and reproducible, driven by enhanced electrospray ionisation, higher charge states, and superior MS2 spectral quality, evidenced by ~2-fold increase in b- and y-ion intensities. Importantly, DMSO did not introduce major sequence bias, preserving motif integrity and predicted binding characteristics. <b>Conclusions:</b> Overall, these findings establish DMSO as a robust additive for improving sensitivity and reliability in immunopeptidomics, particularly for low-input or clinically derived samples.
Authors
- Scott Blundell
- Yue Ding (ORCID: https://orcid.org/0000-0002-5027-6641)
- Terry C. C. Lim Kam Sian
- Pouya Faridi
- Ralf B. Schittenhelm
Institutions
- Discovery Institute (US)
- Hudson Institute of Medical Research (AU)
- Abterra Biosciences (United States) (US)
- Monash University (AU)
Publication Details
- Journal
- Proteomes
- Published
- 2026-03-13
- DOI
- https://doi.org/10.3390/proteomes14010013
- Primary Topic
- vaccines and immunoinformatics approaches
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Research Institute
- State Government of Victoria
- National Health and Medical Research Council